Effect of Remimazolam and Propofol on Postoperative Delirium

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age65-100
SponsorInje University

About this trial

Remimazolam is an ultra-short acting benzodiazepine agonist which is used widely for general anesthesia and sedation. Remimazolam has several advantages. Remimazolam is rapidly metabolized by tissue esterase that it does not accumulate even after infusion for long periods of time. The presence of reversal agents (flumazenil) is also advantageous. Also, hemodynamic stability compared to propofol gives clinicians preference to use for geriatric anesthesia. However, the study on the effect of remimazolam compared to propofol on postoperative delirium have not been carried out. The purpose of the study is to compare the incidence of postoperative delirium and recovery profile in elderly patients undergoing orthopedic surgery using either remimazolam or propofol.

Eligibility criteria

Qualifiers

elderly patients undergoing hip or knee arthroplasty under general anesthesia.

body mass index >30 kg/m2

Disqualifiers

moderate to severe liver dysfunction

moderate to severe renal dysfunction

unable to extubate in the operation room after operation

benzodiazepine dependence

Trial design

Treatments tested in this trial

  • Remimazolam (Byfavo)
  • Propofol

Treatment groups

82 Participants
are divided into 2 treatment groups

Sponsors and collaborators